Abstract
Patients undergoing treatment for acute lymphoblastic leukaemia (ALL) are at risk of coagulopathy, especially thromboembolism. We conducted a survey on practices in the assessment and management of coagulopathy during the new ALLTogether protocol in 29 (17 paediatric, 12 adult) Nordic and Baltic cancer centres. While 92% of adult centres used thromboprophylaxis with low-molecular-weight heparin, no paediatric centre did. Almost all providers performed baseline coagulation studies, but only 59% continued the assessment. Fibrinogen replacement was conducted in 59%, and antithrombin replacement in 28% of the centres. The survey highlights the need for guidelines in the management of coagulopathy during ALL therapy.
Original language | English |
---|---|
Pages (from-to) | 117-121 |
Number of pages | 5 |
Journal | British Journal of Haematology |
Volume | 199 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2022 Oct |
Subject classification (UKÄ)
- Cancer and Oncology
Free keywords
- ALL
- antithrombin
- childhood leukaemia
- paediatric haemostasis
- paediatric thrombosis
- thrombosis